Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials


Marlena Broncel | Paulina Gorzelak-Pabiś | Amirhossein Sahebkar | Katarzyna Serejko | Sorin Ursoniu | Jacek Rysz | Maria Corina Serban | Monika Możdżan | Maciej Banach | Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group
First published: 2015 Oct 12.  |



Statin use might be associated with an increased risk of sleep disturbances including insomnia, but the evidence regarding sleep changes following statin therapy has not been conclusive. Therefore we assessed the impact of statin therapy on sleep changes through a systematic review and meta-analysis of available randomized controlled trials (RCTs).

Material and methods

We searched MEDLINE and SCOPUS up to October 1, 2014 to identify placebo-controlled RCTs investigating the effect of statin therapy on sleep changes. A meta-analysis was performed using either a fixed-effects or a random-effect model according to the I2 statistic. Effect size was expressed as weighted mean difference (WMD) and 95% confidence interval (CI).


Overall, the impact of statin therapy on polysomnography (PSG) indices of sleep was reported in 5 trials comprising 9 treatment arms. Overall, statin therapy had no significant effect on total sleep duration (WMD: –7.75 min, 95% CI: –18.98, 3.48, p = 0.176), sleep efficiency (WMD: 0.09%, 95% CI: –2.27, 2.46, p = 0.940), entries to stage I (WMD: 0.36, 95% CI: –0.91, 1.63, p = 0.580), or latency to stage I (WMD: –1.92 min, 95% CI: –4.74, 0.89, p = 0.181). In contrast, statin therapy significantly reduced wake time (WMD: –4.43 min, 95% CI: –7.77, –0.88, p = 0.014) and number of awakenings (WMD: –0.40, 95% CI: –0.46, –0.33, p < 0.001). Meta-regression did not suggest any correlation between changes in wake time and awakening episodes with duration of treatment and LDL-lowering effect of statins.


The results indicated that statins have no significant adverse effect on sleep duration and efficiency, entry to stage I, or latency to stage I sleep, but significantly reduce wake time and number of awakenings.

Full content publication available for download


Drs Broncel and Banach contributed equally to this meta-analysis.

Conflict of interest

The authors declare no conflict of interest.

  1. Catapano AL, Reiner Ž, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis. 2011;217:1–44. 
  2. Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015;14:935–55.
  3. Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11:1–23. 
  4. Banach M, Malodobra-Mazur M, Gluba A, Katsiki N, Rysz J, Dobrzyn A. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des. 2013;19:4904–12.
  5. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172:1180–2.
  6. Tuccori M, Lapi F, Testi A, et al. Statin-associated psychiatric adverse events. Drug Safety. 2008;31:1115–23
  7. Boriani G, Biffi M, Strocchi E, Branzi A. Nightmares and sleep disturbances with simvastatin and metoprolol. Ann Pharmacother. 2001;35:1292.
  8. Takada M, Fujimoto M, Yamazaki K, Takamoto M, Hosomi K. Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database. Drug Safety. 2014;37:421–31.
  9. Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Therap. 1991;50:730–7. 
  10. Harrison R, Ashton C. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol. 1994;37:231–6.
  11. Barth JD, Kruisbrink O, Van Dijk AL. Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia. BMJ. 1990;301:669. 
  12. Eckernäs S, Roos B, Kvidal P, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmacol. 1993;35:284–9. 
  13. Carlsson CM, Papcke-Benson K, Carnes M, McBride PE, Stein JH. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults. Drugs Aging. 2002;19:793–805.
  14. Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood–brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharmaceut Res. 1994;11:305–11.
  15. Tobert JA, Leslie B, Schaefer E, et al. HMG-CoA reductase inhibitors for hypercholesterolemia. N Engl J Med. 1988;319:1222–3.
  16. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol < 50 mg/dl with rosuvastatin: the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) J Am Coll Cardiol. 2011;57:1666–75. 
  17. Ditschuneit H, Kuhn K. Comparison of different HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1991;40:S27–32. 
  18. Roth T, Richardson GR, Sullivan JP, Lee RM, Merlotti L, Roehrs T. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol. 1992;15:426–32. 
  19. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994;34:989–96.
  20. Partinen M, Pihl S, Strandberg T, et al. Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia. Am J Cardiol. 1994;73:876–80.
  21. Kamei Y, Shirakawa S, Ishizuka Y, et al. Effect of pravastatin on human sleep. Psychiatry Clin Neurosci. 1993;47:643–6. 
  22. Higgins J, Green S. Cochrane Handbook for systematic reviews of interventions version 5.0. 2 [updated September 2009]; The Cochrane Collaboration, 2009. 18 May 2009). 2013. [
  23. Borenstein M, Hedges L, Higgins J, Rothstein H. Englewood, NJ: Biostat; 2005. Comprehensive meta-analysis version 2; p. 104. 
  24. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:1–10. 
  25. Duval S, Tweedie R. Trim and fill: a simple funnel plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63. 
  26. Swiger KJ, Manalac RJ, Blaha MJ, Blumenthal RS, Martin SS. Statins, mood, sleep, and physical function: a systematic review. Eur J Clin Pharmacol. 2014;70:1413–22. 
  27. Black DM, Lamkin G, Olivera EH, Laskarzewski PM, Stein EA. Sleep disturbance and HMG CoA reductase inhibitors. JAMA. 1990;264:1105. 
  28. Ueno R, Honda K, Inoue S, Hayaishi O. Prostaglandin D2, a cerebral sleep-inducing substance in rats. Proc Natl Acad Sci USA. 1983;80:1735–7.
  29. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol. 2010;8:733–41.
  30. Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy. 2006;26:1190–2. 
  31. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy. 2003;23:1663–7.
  32. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother. 2006;40:1880–3. 
  33. Banach M, Aronow WS, Serban C, et al. Lipids, blood pressure and kidney update 2014. Pharmacol Res. 2015;95:111–25. 
  34. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit. 2009;15:MS1–5. 
  35. Banach M, Serban C, Aronow WS, et al. Lipid, blood pressure and kidney update 2013. Int Urol Nephrol. 2014;46:947–61.